DHANVANTRI JEEV | THYROCARE TECHNOLOGIES | DHANVANTRI JEEV/ THYROCARE TECHNOLOGIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 13.5 | 63.8 | 21.2% | View Chart |
P/BV | x | 0.9 | 10.1 | 8.4% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
DHANVANTRI JEEV THYROCARE TECHNOLOGIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DHANVANTRI JEEV Mar-24 |
THYROCARE TECHNOLOGIES Mar-24 |
DHANVANTRI JEEV/ THYROCARE TECHNOLOGIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 28 | 722 | 3.8% | |
Low | Rs | 10 | 430 | 2.4% | |
Sales per share (Unadj.) | Rs | 49.9 | 108.0 | 46.2% | |
Earnings per share (Unadj.) | Rs | 0.4 | 13.1 | 3.1% | |
Cash flow per share (Unadj.) | Rs | 2.5 | 22.0 | 11.4% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 23.1 | 98.7 | 23.4% | |
Shares outstanding (eoy) | m | 4.10 | 52.95 | 7.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.4 | 5.3 | 7.1% | |
Avg P/E ratio | x | 47.2 | 43.9 | 107.5% | |
P/CF ratio (eoy) | x | 7.6 | 26.2 | 28.9% | |
Price / Book Value ratio | x | 0.8 | 5.8 | 14.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 78 | 30,493 | 0.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 43 | 1,079 | 4.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 205 | 5,719 | 3.6% | |
Other income | Rs m | 3 | 94 | 3.1% | |
Total revenues | Rs m | 208 | 5,812 | 3.6% | |
Gross profit | Rs m | 8 | 1,392 | 0.6% | |
Depreciation | Rs m | 9 | 470 | 1.8% | |
Interest | Rs m | 0 | 55 | 0.1% | |
Profit before tax | Rs m | 3 | 960 | 0.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1 | 265 | 0.3% | |
Profit after tax | Rs m | 2 | 695 | 0.2% | |
Gross profit margin | % | 4.1 | 24.3 | 16.8% | |
Effective tax rate | % | 35.4 | 27.6 | 128.2% | |
Net profit margin | % | 0.8 | 12.2 | 6.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 50 | 2,785 | 1.8% | |
Current liabilities | Rs m | 39 | 905 | 4.3% | |
Net working cap to sales | % | 5.7 | 32.9 | 17.5% | |
Current ratio | x | 1.3 | 3.1 | 42.4% | |
Inventory Days | Days | 33 | 114 | 28.9% | |
Debtors Days | Days | 31,291,445 | 3 | 1,127,841,387.9% | |
Net fixed assets | Rs m | 100 | 3,506 | 2.8% | |
Share capital | Rs m | 42 | 530 | 7.8% | |
"Free" reserves | Rs m | 53 | 4,695 | 1.1% | |
Net worth | Rs m | 95 | 5,224 | 1.8% | |
Long term debt | Rs m | 0 | 109 | 0.0% | |
Total assets | Rs m | 150 | 6,291 | 2.4% | |
Interest coverage | x | 43.5 | 18.4 | 237.0% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 1.4 | 0.9 | 149.8% | |
Return on assets | % | 1.1 | 11.9 | 9.5% | |
Return on equity | % | 1.7 | 13.3 | 13.1% | |
Return on capital | % | 2.8 | 19.0 | 14.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0.9 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 51 | 0.0% | |
Fx inflow | Rs m | 0 | 16 | 0.0% | |
Fx outflow | Rs m | 0 | 51 | 0.0% | |
Net fx | Rs m | 0 | -35 | -0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25 | 1,676 | 1.5% | |
From Investments | Rs m | -4 | -913 | 0.4% | |
From Financial Activity | Rs m | NA | -848 | -0.0% | |
Net Cashflow | Rs m | 21 | -85 | -25.1% |
Indian Promoters | % | 19.7 | 71.1 | 27.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 16.7 | - | |
FIIs | % | 0.0 | 1.9 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 80.4 | 28.9 | 278.1% | |
Shareholders | 1,581 | 59,377 | 2.7% | ||
Pledged promoter(s) holding | % | 0.0 | 100.0 | - |
Compare DHANVANTRI JEEV With: APOLLO HOSPITALS NARAYANA HRUDAYALAYA DR. LAL PATHLABS KIMS METROPOLIS HEALTHCARE
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | DHAN JEEVAN | THYROCARE TECHNOLOGIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 0.00% | 4.44% | 0.83% |
1-Month | -3.37% | 12.88% | 1.15% |
1-Year | 51.61% | 75.55% | 46.11% |
3-Year CAGR | 30.11% | -3.68% | 19.60% |
5-Year CAGR | 16.77% | 12.34% | 26.10% |
* Compound Annual Growth Rate
Here are more details on the DHAN JEEVAN share price and the THYROCARE TECHNOLOGIES share price.
Moving on to shareholding structures...
The promoters of DHAN JEEVAN hold a 19.7% stake in the company. In case of THYROCARE TECHNOLOGIES the stake stands at 71.1%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of DHAN JEEVAN and the shareholding pattern of THYROCARE TECHNOLOGIES.
Finally, a word on dividends...
In the most recent financial year, DHAN JEEVAN paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
THYROCARE TECHNOLOGIES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of DHAN JEEVAN, and the dividend history of THYROCARE TECHNOLOGIES.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks experienced a notable rally alongside US equity futures on Monday, marking a positive turn for the markets. The dollar retreated against other currencies as bond yields declined.